Immunotherapy delays type 1 diabetes mellitus in high-risk individuals
Certain individuals at high risk of developing type 1 diabetes mellitis can delay progression to clinical disease by two years or more with a two-week course of teplizumab, according to a phase II study
Source: Shutterstock.com
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 1 | Drugs & Pharmacology | Endocrinology | Immunotherapy | Study